Amylyx Pharmaceuticals, Inc. (AMLX)
$34.82-$2.36 (-6.35%) Today
Gina Mazzariello - Officer
Joshua B. Cohen - Officer
Camille L. Bedrosian - OfficerGina Mazzariello - OfficerAmylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 30,000 | $539K |
| Grant or award | 10 | 308,836 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
49 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James M. Frates - Officer | Open-market sale | Common Stock | 3,326 | $11.11 | $37K | |
| Joshua B. Cohen - Officer | Open-market sale | Common Stock | 7,715 | $11.09 | $86K | |
| Justin B. Klee - Officer | Open-market sale | Common Stock | 7,715 | $11.09 | $86K | |
| Karen Firestone | Open-market purchase | Common Stock | 8,100 | $12.45 | $101K | |
| Camille L. Bedrosian - Officer | Open-market sale | Common Stock | 6,580 | $14.35 | $94K | |
| James M. Frates - Officer | Open-market sale | Common Stock | 10,558 | $14.65 | $155K | |
| Camille L. Bedrosian - Officer | Open-market sale | Common Stock | 12,039 | $14.58 | $176K | |
| Joshua B. Cohen - Officer | Open-market sale | Common Stock | 29,733 | $14.34 | $426K | |
| Joshua B. Cohen - Officer | Open-market sale | Common Stock | 200 | $15.00 | $3K | |
| Justin B. Klee - Officer | Open-market sale | Common Stock | 29,775 | $14.37 | $428K | |
| Justin B. Klee - Officer | Open-market sale | Common Stock | 200 | $15.01 | $3K | |
| Gina Mazzariello - Officer | Open-market sale | Common Stock | 8,828 | $14.58 | $129K | |
| Gina Mazzariello - Officer | Open-market sale | Common Stock | 15,000 | $8.07 | $121K | |
| Gina Mazzariello - Officer | Open-market sale | Common Stock | 15,000 | $8.34 | $125K | |
| George M. Milne Jr. | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| James M. Frates - Officer | Open-market sale | Common Stock | 10,896 | $3.47 | $38K | |
| Camille L. Bedrosian - Officer | Open-market sale | Common Stock | 5,421 | $5.54 | $30K | |
| Justin B. Klee - Officer | Option exercise | Common Stock | 63,690 | $1.57 | $100K | |
| Justin B. Klee - Officer | Option exercise | Stock Option (right to buy) | 63,690 | $0.00 | - | |
| Camille L. Bedrosian - Officer | Open-market sale | Common Stock | 11,442 | $3.20 | $37K | |
| Joshua B. Cohen - Officer | Open-market sale | Common Stock | 18,589 | $3.20 | $59K | |
| Gina Mazzariello - Officer | Open-market sale | Common Stock | 8,709 | $3.20 | $28K | |
| Justin B. Klee - Officer | Open-market sale | Common Stock | 18,589 | $3.20 | $59K |
This is as far as the anonymous view goes. Create a free account for all 49 AMLX filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Amylyx Pharmaceuticals, Inc. (AMLX) had 11 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for AMLX runs to 49 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AMLX were filed in the last 90 days. 2 purchases are on record for this company.
2 insider sales of AMLX were filed in the last 90 days, totaling $539K.
This page tracks AMLX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AMLX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
